[{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BCDA-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"BioCardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Private Placement","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Undisclosed"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Neurokinin 1 Receptor Positive Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BCDA-03","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"StemCardia","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"SCM-102","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ StemCardia","highestDevelopmentStatusID":"4","companyTruncated":"BioCardia \/ StemCardia"},{"orgOrder":0,"company":"BioCardia","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transendocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Transendocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"CellProthera","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Protheracytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Injection","sponsorNew":"BioCardia \/ CellProthera","highestDevelopmentStatusID":"8","companyTruncated":"BioCardia \/ CellProthera"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BCDA-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Cell","moa":"NK-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BioCardia \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia \/ Inapplicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Emory University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BCDA-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial Infusion","sponsorNew":"BioCardia \/ Emory University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"BioCardia \/ Emory University School of Medicine"}]
Find Clinical Drug Pipeline Developments & Deals by BioCardia
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
